Advertisement

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement

Apr

11

Today In Oncology

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

American Cancer Society Announces New Pediatric Adolescent and Young Adult Cancer Journal

Colorectal Cancer Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide

CLL Linked to Increased Skin Cancer Risk and Mortality

Advertisement

© 2026 HSP News Service, L.L.C.